Seeking Alpha

At this point, I'll be quite happy to never hear or read the word "Achillion" again, as my former positive calls on Achillion Pharmaceuticals (ACHN) just keep looking worse and worse. With the company's post-Friday close clinical update, it's very difficult to argue that there's enough value left in this name to bother with it even further. I have no doubt that there will be a "never say die" contingent that wants to stick with this name, and I suppose I can't completely rule out the possibility that the next drug combo will work, but the combination of weak data, questionable reporting of that data, and the emerging competitive landscape just makes it too hard to look...

Only subscribers can access this article, which is part of the PRO research library covering 3,758 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: